熊去氧胆酸对原发性硬化性胆管炎合并溃疡性结肠炎患者发生结直肠肿瘤影响的研究进展  

Advances in research on colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis induced by ursodeoxycholic acid

作　　者：赵春山[1] 王彬[1] 张莉莉[1] 王邦茂[1] ZHAO Chunshan;WANG Bin;ZHANG Lili;WANG Bangmao(Department of Gastroenterology,General Hospital,Tianjin Medical University,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院消化内科,天津300052

出　　处：《胃肠病学和肝病学杂志》2018年第12期1446-1448,共3页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金资助项目(81600425)

摘　　要：熊去氧胆酸(ursodleoxycholic acid,UDCA)是一种合成胆汁酸,作为鹅去氧胆酸的7β-羟基差向异构体,可以改善肝脏的生物化学功能。目前,尽管没有明确的证据表明UDCA能够改善原发性硬化性胆管炎(primary sclerosing cholangitis,PSC)患者的预后,但还是被广泛应用于治疗PSC。PSC是一种慢性胆汁淤积性肝病,其与溃疡性结肠炎(ulcerative colitis,UC)密切相关。PSC-UC患者发生结直肠肿瘤的风险明显高于普通人群。因此,了解UDCA对PSC-UC患者结直肠肿瘤发生的影响、其可能的内在机制及如何应用UDCA对改善PSC-UC患者肿瘤相关的预后至关重要。As the 7β-epimer of chenodeoxycholic acid,ursodeoxycholic acid (UDCA)is a synthetic bile acid and can be used to improve liver biochemistries.At present,although there is no clear evidence that UDCA can improve the prognosis of patients with primary sclerosing cholangitis (PSC),it is still widely used in the treatment of PSC.As a chronic cholestatic liver disease,PSC can be strongly connected with ulcerative colitis (UC).The risk of developing colorectal neoplasia in patients with PSC-UC is higher than that in ordinary people.Therefore,it is very important to understand how UDCA affects the development of colorectal neoplasia,the underlying mechanisms and how UDCA is used to improve the tumor-related prognosis in patients with PSC-UC.

关 键 词：熊去氧胆酸 结直肠肿瘤 溃疡性结肠炎 原发性硬化性胆管炎 

分 类 号：R735.34[医药卫生—肿瘤]